Healio

COPD-related health care usage drops with ensifentrine in moderate to severe COPD

Please provide your email address to receive an email when new articles are posted on . Unscheduled physician office visits, ED visits and unplanned hospitalizations made up the studied COPD-related ...
Healio

Ensifentrine improves outcomes in both moderate, severe COPD

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe COPD experienced improvements with 3 mg of twice-daily ensifentrine. Study ...
Medscape

Ensifentrine Offers COPD Patients Relief and Convenience

The recent Food and Drug Administration (FDA) approval of ensifentrine marks the first new treatment for patients with persistent chronic obstructive pulmonary disease (COPD) in more than a decade, ...
Nasdaq

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that six ...
Monthly Prescribing Reference

Ensifentrine Improves Lung Function, Cuts COPD Exacerbations in Late Stage Trial

Credit: Getty Images. Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions. Treatment with nebulized ...
Nasdaq

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...
FiercePharma

Verona's ensifentrine will be a 'paradigm shift in COPD treatment,' GlobalData says

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat ...
Business Insider

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...
The American Journal of Managed Care

Ensifentrine Shows Promise as Add-On, Stand-Alone Therapy in COPD: M. Bradley Drummond, MD, MHS

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...
MedPage Today

FDA Approves Novel Nebulized Therapy for COPD

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...
Monthly Prescribing Reference

Twice-Daily Ensifentrine Improves COPD Symptoms at Up to 4 Weeks

copd-pulmonology-xray-ca0416 Twice-daily ensifentrine was associated with improvements in several symptoms of COPD, including breathlessness, chest symptoms, cough and sputum, and shortness of breath.
Business Insider

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

LONDON, May 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today presents ...